Time in Target Ambulatory Blood Pressure Range Linked to Lower CV Risk

ICOS-CORE Whitepaper Calls for Rigorous Evidence to Support Cardio-oncology Rehabilitation

Vutrisiran Attenuates Cardiac Decline in ATTR-CM, HELIOS-B Analysis Shows

Tirzepatide Benefits in HFpEF Consistent Across Obesity Levels, SUMMIT Analysis Shows

Heart Rate Lowering Benefits are Context-Dependent, Meta-Analysis Finds

Increased Systolic Blood Pressure Variability Over Time Linked to Higher Risk of CVD, CKD, and Death

ESC Congress 2025 Releases its Late-Breaking Scientific Programme

Hot Line Sessions Revealed for ESC Congress 2025

IMPLEMENT-HF Initiative Raises Quadruple Therapy Use from 4.7% to 44.6% in Heart Failure Care

Intravenous Ferric Carboxymaltose in FAIR-HF2 Trial Shows No Significant Reduction in Heart Failure…